Last reviewed · How we verify
Metoprolol succinate sustained-release tablet
Metoprolol succinate sustained-release tablet, marketed by Sumitomo Pharma (Suzhou) Co., Ltd., is a well-established cardiovascular medication with a strong presence in the market. The key composition patent is set to expire in 2028, providing a significant period of market exclusivity and potential revenue stability. However, the primary risk lies in the potential increase in generic competition following the patent expiry, which could erode market share and revenue.
At a glance
| Generic name | Metoprolol succinate sustained-release tablet |
|---|---|
| Also known as | Betaloc tablet |
| Sponsor | Sumitomo Pharma (Suzhou) Co., Ltd. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis (NA)
- Antihypertensive Drug Selection Based on Hemodynamic Phenotypes (PHASE4)
- Metoprolol and Trimetazidine for Coronary Heart Disease With Angina (NA)
- Low-dose Quadruple Combination Therapy in Patients With Hypertension (PHASE4)
- Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate (PHASE4)
- Study of Statin for Reduction of Postoperative Paroxysmal Atrial Fibrillation (PHASE4)
- Comparison of Bisoprolol With Metoprolol Succinate Sustained-release on Heart Rate and Blood Pressure in Hypertensive Patients (PHASE4)
- The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: